Motilium Fastmelts (Domperidone)

Domperidone blocks dopamine D2 receptors located outside the central nervous system, particularly in the chemoreceptor trigger zone and gastrointestinal smooth muscle. This antagonism increases the tone and coordination of gastric contractions, accelerates emptying, and prevents dopamine‑mediated stimulation of the vomiting centre, resulting in anti‑emetic and pro‑kinetic effects.

The appropriate dose of Motilium Fastmelts is determined by the prescribing healthcare professional based on the patient’s condition, age, renal and hepatic function, and concomitant medications. Clinicians follow local prescribing guidelines and adjust the regimen as needed; patients should follow the prescriber’s instructions exactly.

Safety data for domperidone in pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To request Motilium Fastmelts, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Domperidone differs from other dopamine antagonists such as metoclopramide by having limited central nervous system penetration, which reduces the risk of extrapyramidal side effects. Compared with 5‑HT3 antagonists, it primarily acts peripherally and may be preferred when a pro‑kinetic effect is also desired. Choice of therapy depends on the clinical scenario and patient tolerance.

Motilium Fastmelts should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children. No refrigeration is required for this orally disintegrating tablet formulation.

The tablet is placed on the tongue and allowed to dissolve completely without the need for water. Once the tablet has melted, the patient can swallow the resulting solution. This route provides rapid absorption and is convenient for patients who have difficulty swallowing conventional tablets.

The most serious adverse events include cardiac arrhythmias related to QT‑interval prolongation, especially when combined with other QT‑prolonging agents or CYP3A4 inhibitors, and rare extrapyramidal reactions such as dystonia. Severe allergic reactions, including anaphylaxis, may also occur. Patients should be monitored for these risks, particularly during the early phase of therapy.

Motilium Fastmelts is contraindicated in patients with known prolonged QT interval, significant cardiac arrhythmias, or a history of ventricular tachyarrhythmia. It should also be avoided in individuals with prolactin‑secreting tumors, severe hepatic impairment, or those taking strong CYP3A4 inhibitors without appropriate monitoring. Pregnant or breastfeeding women should use it only if clearly indicated by a physician.